Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of β-chemokines in contrast to infected humans

Journal of Medical Virology

Volumn 69, Issue 3, 2003, Pages 297-305

  Ondoa, Pascale ^a   Vereecken, Chris ^a   Fransen, Katrien ^a   Colebunders, Robert ^a   Van der Groen, Guido ^a   Heeney, Jonathan L ^b   Kestens, Luc ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Animal models for lentivirus infection; Resistance to AIDS

Indexed keywords

BETA CHEMOKINE; CD8 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CHIMPANZEE; CONTROLLED STUDY; CYTOFLUOROMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; PAN TROGLODYTES; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; PAN (APE); PAN TROGLODYTES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0037361401     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10289     Document Type: Article

References (60)

1. Aukrust P, Muller F, Froland SS. 1998. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 177:1091-1096.
2. Balla Jhagjhoorsingh SS, Koopman G, Mooij P, Haaksma TG, Teeuwsen VJ, Bontrop RE, Heeney JL. 1999. Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. J Immunol 162:2308-2314.
3. + cells correlates with the clinical status of HIV-infected individuals. Proc Natl Acad Sci USA 93:13125-13130.
4. + T cells. J Immunol 144:1462-1466.
5. Bubel S, Wilhem D, Entelmann M, Kirchner H, Kluter H. 1996. Chemokines in stored platelet concentrates. Transfusion 36:445-449.
6. Clerici M, Balotta C, Trabattoni D, Papagno L, Ruzzante S, Rusconi S, Fusi ML, Colombo MC, Galli M. 1996. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 10:1432-1433.
7. Cocchi F, Devico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8(+) T cells. Science 270:1811-1815.
8. + and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES. Eur J Immunol 25:751-756.
9. Fehniger TA, Herbein G, Yu HX, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA. 1998. Natural killer cells from HIV-1(+) patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 161:6433-6438.
10. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, Longhi R, Loverro P, Borgonovo B, Gaffi D, Carrow E, Malnati M, Lusso P, Siccardi AG, Lazzarin A, Beretta A. 1997. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 186:455-460.
11. Gao F, Bailes E, Robertson DL, Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441.
12. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC. 1999. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 96:11986-11991.
13. + lymphocytes from macaques immunized with live attenuated SIV. J Virol 72:6315-6324.
14. Gougeon ML, Lecoeur H, Boudet F, Ledru E, Marzabal S, Boullier S, Roue R, Nagata S, Heeney J. 1997. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol 158:2964-2976.
15. Heeney JL. 1995. A disease of impaired Th-cell renewal. Immunol Today 16:515-520.
16. Heeney J, Jonker R, Koornstra W, Dubbes R, Niphuis H, Di Rienzo AM, Gougeon ML, Montagnier L. 1993. The resistance of HIV-infected chimpanzees to progression to AIDS correlates with absence of HIV-related T-cell dysfunction. J Med Primatol 22:194-200.
17. Heeney JL, Bruck C, Goudsmit J, Montagnier L, Schultz A, Tyrrell D, Zolla-Pazner S. 1997. Immune correlates of protection from HIV infection and AIDS. Immunol Today 18:4-8.
18. Jansson M, Popovic M, Karlsson A, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H. 1996. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 93:15382-15387.
19. Jennes W, Sawadogo S, Koblavi-Dème S, Vuylsteke B, Maurice C, Roels TH, Chorba T, Nkengasong JN, Kestens L. 2002. Positive association between β-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses 18:171-177.
20. Katzenstein DA, Hammer SM, Hughes MD. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleosides therapy in HIV-infected adults with 200 to 500 CD4 cell per cubic millimeter. N Engl J Med 335:1091-1098.
21. Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F, Bach BA. 1992. Expression of activation antigens, HLA-DR and CD38 on CD8 lymphocytes during HIV-1 infection. AIDS 6:793-797.
22. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, Gigase PL. 1994. Selective increase of activation antigens HLA-DR and CD38 on CD4(+)CD45RO(+) T lymphocytes during HIV-1 infection. Clin Exp Immunol 95:436-441.
23. Kestens L, Vingerhoets J, Peeters M, Vanham G, Vereecken C, Penne G, Niphuis H, van Eerd P, van der Groen G, Gigase P. 1995. Phenotypic and functional parameters of cellular immunity in a chimpanzee with a naturally acquired simian immunodeficiency virus infection. J Infect Dis 172:957-963.
24. cpz causes non-escalating immune activation and uses multiple co-receptors in chimpanzees. 12th World AIDS Conference, Geneva, June 28 - July 3; Abstract no. 11210.
25. Klinger MH, Whilelm D, Bubel S, Sticherling M, Scroeder JM, Kuhnel W. 1995. Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 107:541-546.
26. + cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 15:365-373.
27. Kreuzer KA, Rockstroh JK, Kupfer B, Spengler U. 2000. Endogenous levels of C-C chemokines MIP-1 alpha, MIP-1 beta, and RANTES do not reflect the disease course in HIV-1-seropositive individuals. Int J Clin Lab Res 30:163-168.
28. + T-cell-mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta. AIDS 11:575-580.
29. Levy JA, Mackewicz CE, Barker E. 1996. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8(+) T cells. Immunol Today 17:217-224.
30. + cell anti HIV activity correlates with the clinical states of the infected individual. J Clin Invest 87:1462-1466.
31. Mackewicz CE, Barker E, Greco G, Reyesteran G, Levy JA. 1997. Do β-chemokines have clinical relevance in HIV infection? J Clin Invest 100:921-930.
32. + T cells. AIDS Res Hum Retroviruses 15:1453-1460.
33. McKenzie SW, Dallalio G, North M, Frame P, Means RT. 1996. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 10:F29-F33.
34. Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ. 1997. Effect of immunization with an inactivated gp120-depleted HIV immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 14:343-350.
35. Moss RB, Wallace MR, Lanza P, Giermakowska W, Jensen FC, Theofan G, Chamberlin C, Richieri SP, Carlo DJ. 1998. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV immunogen (remune). Clin Diagn Lab Immunol 5:308-312.
36. + T cells in HIV-1 infected individuals. Intervirology 40:263-270.
37. Norley S, Beer B, Holzammer S, zur Megede J, Kurth R. 1999. Why are the natural host of SIV resistant to AIDS? Immunol Lett 66:47-52.
38. Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O'Neil SP, Brown CR II, Hart CE, Guenthner PC, Swenson RB, McClure HM. 1997. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 71:4086-4091.
39. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW, Fauci AS. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 102:223-231.
40. cpz-infected chimpanzees. J Med Primatol 30:243-253.
41. + T cells but not by natural killer cells on infected chimpanzees. AIDS Res Hum Retroviruses 18:373-382.
42. Oravecz T, Pall M, Norcross MA. 1996. Beta-chemokine inhibition of monocytotropic HIV-1 infection: interference with a postbinding fusion step. J Immunol 157:1329-1332.
43. Peeters M, Fransen K, Delaporte E, Vanden Haesevelde M, Gershy-Damet GM, Kestens L, van der Groen G, Piot P. 1992. Isolation and characterization of a new chimpanzee lentivirus (simian immunodeficiency virus isolate cpz-ant) from a wild-captured chimpanzee. AIDS 6:447-451.
44. Richman DD. 1996. HIV therapeutics. Science 272:1886-1888.
45. + T cell responses associated with the control of viremia. Science 278:1447-1450.
46. Schwartz DH, Castillo RC, Arango-Jaramillo S, Sharma UK, Song HF, Sridharan G. 1997. Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in log-term and recently infected HIV-1-positive persons. J Infect Dis 176:1168-1174.
47. Tartakovsky B, Turner D, Vardinon N, Burke M, Yust I. 1999. Increased intracellular accumulation of macrophage inflammatory protein-1 beta and its decreased secretion correlate with advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 20:420-442.
48. ten Haaft PJF, Cornelissen M, Goudsmit J, Koornstra W, Dubbes R, Niphuis H, Peeters M, Thiriart C, Bruck C, Heeney JL. 1995. Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination. J Gen Virol 76:1015-1020.
49. ten Haaft PJF, Verstrepen B, Uberla K, Rosenwirth B, Heeney JL. 1998. A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian human immunodeficiency virus-infected macaques. J Virol 72:10281-10285.
50. cpz in chimpanzees. AIDS 15:1-8.
51. Ullum H, Cozzi-Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinhoj P, Pedersen BK. 1998. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory proteins are associated with a decreased risk of HIV disease progression. J Infect Dis 133:331-336.
52. Vanden Haesevelde MM, Peeters M, Jannes G, Janssens W, van der Groen G, Sharp PM, Saman E. 1996. Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology 221:346-350.
53. Villinger F, Brar SS, Brice GT, Chikkala NF, Novembre FJ, Mayne AE, Bucur S, Hillyer CD, Ansari AA. 1997. Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. J Med Primatol 26:11-18.
54. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566.
55. + cell varies among HIV infected individuals. Cell Immunol 119:470-475.
56. Wang Y, Tao L, Mitchell E, Bogers WM, Doyle C, Bravery CA, Bergmeier LA, Kelly CG, Heeney JL, Lehner T. 1998. Generation of CD8 suppressor factor and β-chemokines induced by xenogeneic immunization, in the prevention of simian immunodeficiency infection in macaques. Proc Natl Acad Sci USA 95:5223-5228.
57. Wasik TJ, Bratisiewicz J, Wierzbicki A, Whiteman VE, Rutstein RR, Starr SE, Douglas SD, Kaufman D, Sison AV, Polansky M, Lischner HW, Kozbor D. 1999. Protective role of β-chemokines associated with HIV-specific Th response against perinatal HIV transmission. J Immunol 162:4355-4364.
58. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC. 1998. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95:3857-3861.
59. Zanussi S, Dandrea M, Simonelli C, Battiston V, Tirelli U, Depaoli P. 1996. CD8(+) cells in HIV infection produce macrophage inflammatory protein-1 alpha and RANTES: A comparative study in long term survivors and progressor patients. Immunol Lett 53:105-108.
60. + cells. J Immunol 144:2992-2998.